Aromatase inhibitor and tamoxifen use and the risk of venous thromboembolism in breast cancer survivors
ConclusionsThese findings supplement existing evidence to inform treatment decisions that balance cancer control and cardiovascular toxic outcomes.
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Cardiology | Cardiovascular | Chemotherapy | Electronic Health Records (EHR) | Endocrine Therapy | Heart | Hormones | Pulmonary Thromboembolism | Study | Tamoxifen | Thrombosis | Toxicology | Women